Michael Eisenhauer, MD
Interventional Cardiology · Great Falls, MTNPI 1821064510
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Siemens Medical Solutions USA, Inc. accounts for 87.6% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $17,936 and has fallen 88.8% since, to $2,000 in 2025.
Across 291 payments — averaging $157.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$40K
- Johnson & Johnson$667
- Amgen$658
- Novartis$644
- E.r. Squibb & Sons, L.L.C.$569
- Abbott$465
- plus $3K from 31 others
What the payments were for
- Consulting fees$20,90046%
- Travel & lodging$18,61141%
- Food & beverage$6,36214%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 21 | $40,219 |
| Johnson & Johnson | 32 | $667 |
| Amgen | 34 | $658 |
| Novartis | 35 | $644 |
| E.r. Squibb & Sons, L.L.C. | 30 | $569 |
| Abbott | 12 | $465 |
| Merck | 26 | $424 |
| AstraZeneca | 18 | $318 |
| Actelion Pharmaceuticals US, Inc. | 7 | $225 |
| Sanofi-aventis U.S. LLC | 5 | $224 |
| Biotronik Inc. | 3 | $220 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $189 |
| Pfizer | 7 | $169 |
| Esperion Therapeutics, Inc. | 7 | $145 |
| Chiesi USA, Inc. | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 5 | $79 |
| Medtronic(2 entities) | 3 | $75 |
| Lundbeck LLC | 4 | $55 |
| Boehringer Ingelheim | 3 | $49 |
| Impulse Dynamics (USA) Inc. | 1 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Sanofi | 2 | $35 |
| Philips North America LLC | 2 | $29 |
| Terumo Medical Corporation | 1 | $29 |
| Edwards Lifesciences | 1 | $28 |
| Heartflow, Inc. | 1 | $28 |
| Abiomed | 1 | $22 |
| GE HealthCare | 1 | $19 |
| Getinge USA Sales, LLC | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Lemaitre Vascular, Inc. | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Shockwave Medical, Inc | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Artis icono floor$9,071
How this compares
$45,906 in reported general payments places this provider in the 85th percentile of 22 interventional cardiology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $109,597 |
| XareltoRivaroxaban | 28 | $29,357 |
| EntrestoSacubitril/Valsartan | 21 | $24,441 |
| FarxigaDapagliflozin Propanediol | 14 | $14,661 |
| BrilintaTicagrelor | 18 | $8,836 |
| MultaqDronedarone Hcl | 11 | $8,484 |
| Metoprolol Succinate | 198 | $2,748 |
| Atorvastatin Calcium | 221 | $2,149 |
| Digoxin | 12 | $1,874 |
| Ezetimibe | 71 | $1,106 |
| Losartan Potassium | 95 | $1,016 |
| ClopidogrelClopidogrel Bisulfate | 74 | $1,000 |
| Potassium Chloride | 16 | $895 |
| Carvedilol | 99 | $780 |
| Lisinopril | 107 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $169 | $109,597103 claims |
| Johnson & JohnsonXarelto | $667 | $29,35728 claims |
| NovartisEntresto | $644 | $24,44121 claims |
| AstraZenecaFarxiga, Brilinta | $318 | $23,49632 claims |
| Sanofi-aventis U.S. LLCMultaq | $224 | $8,48411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 22 interventional cardiology providers in Montana.
Other interventional cardiology in Great Falls
- Steven GoldbergGreat Falls$134K
- Shawn KellyGreat Falls$6K
- Daniel SpoonMissoula$58K
- Robert MinorBillings$46K
- Joshua VogtKalispell$41K
- Claudia Lama von BuchwaldBillings$29K
- Per SommerBillings$27K
- James MadduxMissoula$26K
- Robert TerryBillings$12K
- William HullButte$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.